Mezzion Pharma Co., Ltd. Logo

Mezzion Pharma Co., Ltd.

Develops and out-licenses novel therapeutics like udenafil, with a focus on rare diseases.

140410 | KO

Overview

Corporate Details

ISIN(s):
KR7140410002
LEI:
Country:
South Korea
Address:
서울특별시 강남구 삼성로 570 석천빌딩 7층, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Mezzion Pharma Co., Ltd. is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics, with a particular emphasis on rare diseases. The company's primary efforts are centered on its drug candidate, udenafil, for various medical conditions. A key initiative is the development of udenafil for adolescents living with Fontan circulation, a rare congenital heart condition, supported by a large-scale Phase 3 clinical trial (FUEL-2). Mezzion's pipeline also includes potential treatments for pulmonary arterial hypertension (PAH), portal hypertension, and erectile dysfunction. The company's business model involves developing pharmaceutical products and out-licensing them for international markets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-17 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 14.7 KB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-08 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 27.9 KB
2025-06-20 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 6.0 KB
2025-06-20 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 6.0 KB
2025-06-13 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 101.3 KB
2025-06-13 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 107.8 KB
2025-06-10 00:00
Share Issue/Capital Change
주요사항보고서(전환사채권발행결정)
Korean 67.0 KB
2025-06-10 00:00
Share Issue/Capital Change
주요사항보고서(전환사채권발행결정)
Korean 94.9 KB
2025-06-05 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 27.1 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 972.3 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 24.7 KB
2025-03-20 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.5 MB
2025-03-14 00:00
Audit Report / Information
감사보고서제출
Korean 25.8 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 143.7 KB

Automate Your Workflow. Get a real-time feed of all Mezzion Pharma Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mezzion Pharma Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mezzion Pharma Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Faes Farma S.A. Logo
Develops and markets pharmaceuticals, like antihistamines, and animal nutrition products globally.
Spain
FAE
Fagron N.V. Logo
Supplies compounding ingredients and solutions for personalized medicine to healthcare professionals.
Belgium
FAGR
Farmak Logo
A pharmaceutical manufacturer and exporter of 400+ medicines to over 50 countries.
Ukraine
FARM
Farmsintez ao Logo
Produces APIs & hospital drugs for oncology & specialty diseases; offers contract services.
Russian Federation
LIFE
FATE THERAPEUTICS INC Logo
Develops off-the-shelf iPSC cell therapies for cancer and autoimmune diseases.
United States of America
FATE
FENNEC PHARMACEUTICALS INC. Logo
Prevents chemotherapy-induced hearing loss in children with its sole product, PEDMARK®.
United States of America
FENC
FibroBiologics, Inc. Logo
Clinical-stage biotech developing fibroblast cell therapies for chronic diseases.
United States of America
FBLG
FIBROGEN INC Logo
Biopharma developing first-in-class therapies for cancer, anemia, and serious conditions.
United States of America
FGEN
Fine Foods & Pharmaceuticals Ntm Logo
Contract development & manufacturing of oral solids for pharma, nutraceutical & cosmetic sectors.
Italy
FF
Flora Growth Corp. Logo
A diversified firm in pharma distribution, plant-based wellness, and digital assets.
United States of America
FLGC

Talk to a Data Expert

Have a question? We'll get back to you promptly.